Tatva Chintan Pharma Chem Reports Strong Q2FY27 Results
Tatva Chintan Pharma Chem Ltd · Investor Presentation · 19 Oct 2026, 11:37 pm
Tatva Chintan Pharma Chem Reports Strong Q2FY27 Results Tatva Chintan Pharma Chem reported a 76% YoY surge in Q2FY27 revenue from operations to ₹2,173 Mn, while EBITDA (excluding other income) rose 83% YoY to ₹407 Mn with a 19% margin. Q2FY27 PAT surged 116% YoY to ₹215 Mn (EPS of ₹9.17). For H1FY27, revenue reached ₹3,844 Mn (up 60% YoY) and PAT expanded 126% YoY to ₹374 Mn. In Q2FY27, SDA contributed 45% of revenue, driven by EURO 7 emission standard adoption, followed by PASC at 30% and PTC at 21%.
Original exchange filing (PDF)
More announcements from Tatva Chintan Pharma Chem Ltd
- Updated Investor Presentation. · 20 Oct 2026
- Earnings Call scheduled to be held on Monday, 19 October 2026 at 05:00 p.m. (IST) has been cancelled due to unforeseen circumstances. · 19 Oct 2026
- Outcome Of the Board Meeting Held On 19.10.2026 · 19 Oct 2026
- Enclosed · 19 Oct 2026
- Tatva Chintan Pharma Chem Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 19 Oct 2026
- Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. · 16 Oct 2026
- Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we would like to inform you that the Earnings Call post announcement of .... · 19 Oct 2026
- TATVA CHINTAN PHARMA CHEM LIMITED has informed the Exchange about Board Meeting to be held on 19-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 . · 19 Oct 2026
